Clinical trial
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients…
NCT00049010 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00049010 |
|---|---|
| Title | Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma |
| Official title | Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Genetic, Other |
| Interventions | comparative genomic hybridization, cytogenetic analysis, fluorescence in situ hybridization, immunohistochemistry staining method |
| Enrollment | 314 |
| Start date | Sep 1, 2002 |
| Primary completion | Mar 1, 2006 |
| Completion | Oct 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 1, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: